Page last updated: 2024-12-08

L-cycloserine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

L-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has S configuration. An antibiotic isolated from Erwinia uredovora. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID449215
CHEMBL ID448864
CHEBI ID75592
SCHEMBL ID243772

Synonyms (95)

Synonym
(4s)-4-aminoisoxazolidin-3-one
339-72-0
(s)-3-isoxazolidinone, 4-amino-
PRESTWICK2_001086
PRESTWICK3_001086
3-isoxazolidinone, 4-amino-, (l)-
levcycloserine
(-)-4-amino-3-isossazolidone [italian]
3-isoxazolidinone, 4-amino-, (s)-
l-oxamicina [italian]
(s)-4-amino-3-isoxazolidinone
cyclo-l-serine
l-4-amino-3-isoxazolidinone
levcicloserina [inn-spanish]
(s)-(-)-cycloserine
l-4-aminoisoxazolidin-3-one
levcycloserinum [inn-latin]
levcycloserine [usan:inn]
brn 0080799
einecs 206-427-0
EU-0100199
BPBIO1_001246
D04706
levcycloserine (usan/inn)
LOPAC0_000199
BSPBIO_001132
4ax ,
AB00514038
l-cycloserine
MLS000859981
smr000326840
PRESTWICK1_001086
PRESTWICK0_001086
SPBIO_003026
NCGC00093674-02
NCGC00093674-03
NCGC00093674-01
(s)-4-amino-3-isoxazolidone
C 1159
NCGC00093674-04
(4s)-4-amino-1,2-oxazolidin-3-one
chebi:75592 ,
nsc-760409
cycloserine, l-
CHEMBL448864
HMS1571I14
HMS2098I14
HMS3260H19
HMS3264E06
AKOS006237181
(-)-4-amino-3-isoxazolidinone
(s)-4-amino-isoxazolidin-3-one
l-cs
(-)-4-aminoisoxazolidin-3-one
(-)-cycloserine
CCG-204294
(s)-4-aminoisoxazolidin-3-one
HMS2235N07
S3945
bdbm50357231
(-)-4-amino-3-isossazolidone
4-27-00-05550 (beilstein handbook reference)
nsc 760409
levcycloserinum
l-oxamicina
ak7drb7fmo ,
levcicloserina
unii-ak7drb7fmo
LP00199
levcycloserine [inn]
levcycloserine [usan]
SCHEMBL243772
FD3007
CS-4717
NCGC00260884-01
tox21_500199
J-502461
HY-B1122
AB00514038_05
mfcd00064324
(s)-cycloserine
sr-01000780566
SR-01000780566-2
3-isoxazolidinone, 4-amino-, (4s)-
gtpl9488
HMS3715I20
Q27145415
DS-18395
DTXSID701017231
SDCCGSBI-0050187.P002
NCGC00093674-08
4-azaniumyl-4,5-dihydro-1,2-oxazol-3-olate
NCGC00093674-07
EN300-768780
Z1201618622

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Finally, 20 and 33 were proved to target Ddl in bacterio via intracellular LC-MS dosage of d-Ala, l-Ala and d-Ala-d-Ala."( Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
Ameryckx, A; Frédérick, R; Pochet, L; Saadi, BE; Van Bambeke, F; Wang, G; Wouters, J; Yildiz, E, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
anticonvulsantA drug used to prevent seizures or reduce their severity.
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitorAn EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor that interferes with the action of serine palmitoyltransferase (EC 2.3.1.50).
anti-HIV agentAn antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
4-amino-1,2-oxazolidin-3-oneA member of the class of oxazolidines that is isoxazoldin-3-one which is substituted at position 4 by an amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
endonuclease IVEscherichia coliPotency0.89130.707912.432431.6228AID1708
dopamine D1 receptorHomo sapiens (human)Potency4.61090.00521.30228.1995AID624455
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.89130.100020.879379.4328AID588453
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency14.12540.707912.194339.8107AID720542
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency10.60740.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00280.540617.639296.1227AID2364; AID2528
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
monoatomic ion transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transportProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transportProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid import across plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transportProton-coupled amino acid transporter 1Homo sapiens (human)
proline transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
proton transmembrane transportProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transportProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
amino acid:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
proline:proton symporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
taurine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
protein bindingProton-coupled amino acid transporter 1Homo sapiens (human)
amino acid transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-alanine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
L-proline transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
glycine transmembrane transporter activityProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
lysosomal membraneProton-coupled amino acid transporter 1Homo sapiens (human)
endoplasmic reticulumProton-coupled amino acid transporter 1Homo sapiens (human)
plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
apical plasma membraneProton-coupled amino acid transporter 1Homo sapiens (human)
vacuolar membraneProton-coupled amino acid transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (50)

Assay IDTitleYearJournalArticle
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1692405Antibacterial activity against hospital-acquired vancomycin resistant Staphylococcus aureus VRS-1 assessed as reduction in bacterial growth incubated for 18 to 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID630741Inhibition of human PAT1-mediated L-[3H]proline uptake in human Caco2 cells after 10 mins by liquid scintillation counting2011Bioorganic & medicinal chemistry, Nov-01, Volume: 19, Issue:21
Three-dimensional quantitative structure-activity relationship analyses of substrates of the human proton-coupled amino acid transporter 1 (hPAT1).
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1072954Reduction in intracellular dipeptide D-alanyl-D-alanine pool size in Mycobacterium tuberculosis H37Rv at MIC by filter-based mass spectrometry technique2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID1692404Antibacterial activity against hospital-acquired methicillin/ciprofloxacin and moxifloxacin resistant Staphylococcus aureus SA481 assessed as reduction in bacterial growth incubated for 18 to 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID1072957Antimycobacterial activity against Mycobacterium tuberculosis H37Rv at 0.25 to 16 times MIC after 7 days in presence of L-Alanine2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID1692414Inhibition of Ddl in Staphylococcus aureus ATCC 25923 assessed as increase in D-Ala/D-Ala-D-Ala ratio at 2 times MIC incubated for 30 mins by UHPLC-MS/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID1692399Antibacterial activity against vancomycin resistant Enterococcus faecalis JH2-2::C1 harboring constitutive expression of Ddl and vanB ligase assessed as reduction in bacterial growth incubated for 18 to 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID1692408Disruption of bacterial cell membrane in Staphylococcus aureus ATCC 25923 assessed as increase in PI uptake at 1 to 5 times MIC measured every 10 mins for 2 hrs by PI dye based spectrophotometry2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID1692395Inhibition of recombinant Enterococcus faecalis C-terminal His6-tagged DdlB expressed in Escherichia coli LMG194 using D-Ala as substrate preincubated with enzyme for 30 mins followed by substrate addition and measured after 20 mins by malachite green bas2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID1692397Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as reduction in bacterial growth incubated for 18 to 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID1692400Antibacterial activity against vancomycin resistant Enterococcus faecalis BM4575 harboring VanE genotype, constitutive expression of Ddl and VanE D-Ala-D-Ser ligase assessed as reduction in bacterial growth incubated for 18 to 24 hrs by broth microdilutio2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1692396Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as reduction in bacterial growth incubated for 18 to 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID1692398Antibacterial activity against vancomycin resistant Enterococcus faecalis BM4390 harboring VanB mutant with inactive Ddl and constitutive expression of D-Ala-D-Lac assessed as reduction in bacterial growth incubated for 18 to 24 hrs by broth microdilution2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID1072945Ratio of MIC for Mycobacterium tuberculosis H37Rv in presence of D-Alanine to MIC for Mycobacterium tuberculosis H37Rv2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID1692401Antibacterial activity against methicillin resistant and vancomycin intermediate resistant Staphylococcus aureus MU50 assessed as reduction in bacterial growth incubated for 18 to 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID1072953Reduction in intracellular total Alanine pool size in Mycobacterium tuberculosis H37Rv at MIC by filter-based mass spectrometry technique2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID1692402Antibacterial activity against methicillin and linezolid resistant Staphylococcus aureus NRS119 assessed as reduction in bacterial growth incubated for 18 to 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID377223Inhibition of Concanavalin A-stimulated cell proliferation in mouse splenocytes after 48 hrs by MTT assay2000Journal of natural products, Sep, Volume: 63, Issue:9
In vitro antiinflammatory effects of neolignan woorenosides from the rhizomes of Coptis japonica.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1692403Antibacterial activity against community-acquired methicillin and erythromycin resistant Staphylococcus aureus SA325 assessed as reduction in bacterial growth incubated for 18 to 24 hrs by broth microdilution method2020European journal of medicinal chemistry, Aug-15, Volume: 200Pharmacomodulations of the benzoyl-thiosemicarbazide scaffold reveal antimicrobial agents targeting d-alanyl-d-alanine ligase in bacterio.
AID1072958Antimycobacterial activity against Mycobacterium tuberculosis H37Rv at 0.25 to 16 times MIC after 7 days in presence of D-Alanine2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Metabolomics Reveal d-Alanine:d-Alanine Ligase As the Target of d-Cycloserine in
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (13.64)29.6817
2010's11 (50.00)24.3611
2020's8 (36.36)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.46

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.46 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.46)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]